Elan Reports Second Quarter 2007 Financial ResultsPharmaLive.com (press release), PA - Jul 26, 2007… quarter of 2007 includes $2.2 million (2006: $8.5 million) of amortized revenue related to the licensing of rights to Elan's generic form of Adalat CC. …
Read full story
Elan Reports Second Quarter 2007 Financial ResultsAmerican Digital Networks (press release), MD - 3 hours ago… quarter of 2007 includes $2.2 million (2006: $8.5 million) of amortized revenue related to the licensing of rights to Elan's generic form of Adalat CC. …
Read full story
Actavis Launches Generic Adalat CC Tablets In USeMaxHealth.com, NC - Jun 27, 2007Actavis' NIFEdepine extended-release (XR) tablets are the generic equivalent of Bayer's Adalat CC tablets and available in 30mg and 60mg strengths. …
Read full story
Actavis Launches Generic Adalat CC Tablets in the USPharmaLive.com (press release), PA - Jun 26, 2007Actavis' NIFEdepine extended-release (XR) tablets are the generic equivalent of Bayer's Adalat(R) CC tablets and available in 30mg and 60mg strengths. …
Read full story
Actavis Launches Generic Adalat(R) CC Tablets in the USPR Newswire (press release), NY - Jun 26, 2007Actavis' NIFEdepine extended-release (XR) tablets are the generic equivalent of Bayer's Adalat(R) CC tablets and available in 30mg and 60mg strengths. …
Read full story
Actavis Launches Generic Adalat CC Tablets in the USPrimenewswire (press release), CA - 8 hours agoActavis' NIFEdepine extended-release (XR) tablets are the generic equivalent of Bayer's Adalat(r) CC tablets and available in 30mg and 60mg strengths. …
Read full story
Actavis Launches Generic Adalat TabletsFDA news (subscription), VA - 24 minutes agoActavis’ NIFEdipine XR tablets are the generic equivalent of Bayer’s Adalat CC tablets and available in 30- and 60-mg strengths, Actavis said. …
Read full story
Elan Reports First Quarter 2007 Financial ResultsPharmaLive.com (press release), PA - 8 hours ago… quarter of 2007 includes $2.3 million (2006: $8.5 million) of amortized revenue related to the licensing of rights to Elan's generic form of Adalat CC. …
Read full story
Elan Reports First Quarter 2007 Financial ResultsBusiness Wire (press release), CA - 3 hours ago… quarter of 2007 includes $2.3 million (2006: $8.5 million) of amortized revenue related to the licensing of rights to Elan’s generic form of Adalat CC. …
Read full story
Biovail Reports Record Fourth Quarter, Year-End 2006 Financial ResultsCNW Telbec (Communiqués de presse), Canada - 7 hours ago… Inc. (Watson), a $2.7-million litigation settlement related to the Company's licensing in 1999 of Adalat CC products from Elan Corporation, plc (Elan), …
Read full story